IL164652A0 - Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside - Google Patents

Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside

Info

Publication number: IL164652A0
Authority: IL; Israel
Prior art keywords: blocker; administration; calcium channel; cardiac glycoside; adenosine agonist
Prior art date: 2002-04-18

Application number

IL16465204A

Other languages

English (en)

Original Assignee

Cv Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-18

Filing date

2004-10-18

Publication date

2005-12-18

2004-10-18 Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc

2005-12-18 Publication of IL164652A0 publication Critical patent/IL164652A0/xx

Links

229940127291 Calcium channel antagonist Drugs 0.000 title abstract 2
206010003119 arrhythmia Diseases 0.000 title abstract 2
230000006793 arrhythmia Effects 0.000 title abstract 2
239000002876 beta blocker Substances 0.000 title abstract 2
229940097320 beta blocking agent Drugs 0.000 title abstract 2
239000000480 calcium channel blocker Substances 0.000 title abstract 2
229940097217 cardiac glycoside Drugs 0.000 title abstract 2
239000002368 cardiac glycoside Substances 0.000 title abstract 2
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 title abstract 2
239000003379 purinergic P1 receptor agonist Substances 0.000 title abstract 2
229930002534 steroid glycoside Natural products 0.000 title abstract 2
101150007969 ADORA1 gene Proteins 0.000 abstract 1
229940122614 Adenosine receptor agonist Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)

IL16465204A 2002-04-18 2004-10-18 Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside IL164652A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US37376602P	2002-04-18	2002-04-18
PCT/US2003/012043 WO2003088978A1 (en)	2002-04-18	2003-04-18	Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside

Publications (1)

Publication Number	Publication Date
IL164652A0 true IL164652A0 (en)	2005-12-18

Family

ID=29251078

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL16465204A IL164652A0 (en)	2002-04-18	2004-10-18	Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside

Country Status (17)

Country	Link
US (3)	US7005425B2 (de)
EP (1)	EP1494685B1 (de)
JP (1)	JP2005530736A (de)
KR (1)	KR20040106354A (de)
CN (2)	CN101385738A (de)
AT (1)	ATE418991T1 (de)
AU (1)	AU2003235466C1 (de)
CA (1)	CA2482928A1 (de)
DE (1)	DE60325572D1 (de)
ES (1)	ES2318129T3 (de)
IL (1)	IL164652A0 (de)
MX (1)	MXPA04010285A (de)
NO (1)	NO20045005L (de)
NZ (1)	NZ536001A (de)
RU (1)	RU2332220C2 (de)
WO (1)	WO2003088978A1 (de)
ZA (1)	ZA200408411B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4949558B2 (ja)	1999-03-23	2012-06-13	ハイバーネーション・セラピューティクス・グローバル・リミテッド	臓器の停止、保護、及び保存
USRE47351E1 (en)	1999-06-22	2019-04-16	Gilead Sciences, Inc.	2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en)	1999-06-22	2002-06-11	Cv Therapeutics, Inc.	N-pyrazole A2A adenosine receptor agonists
CA2671940A1 (en)	2000-02-23	2001-08-30	Cv Therapeutics, Inc.	Identification of partial agonists of the a2a adenosine receptor
US7157440B2 (en) *	2001-07-13	2007-01-02	Cv Therapeutics, Inc.	Partial and full agonists of A1 adenosine receptors
US7713946B2 (en)	2002-07-11	2010-05-11	Cv Therapeutics, Inc.	Partial and full agonists A1 adenosine receptors
ATE418991T1 (de) *	2002-04-18	2009-01-15	Cv Therapeutics Inc	Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
US8470801B2 (en)	2002-07-29	2013-06-25	Gilead Sciences, Inc.	Myocardial perfusion imaging methods and compositions
GB2436255B (en) *	2002-12-23	2007-11-28	Global Cardiac Solutions Pty L	Organ preconditioning, arrest, protection, preservation and recovery
CN1980946A (zh) *	2004-07-12	2007-06-13	Cv医药有限公司	用于制备a1腺苷受体激动剂的方法
US20060019954A1 (en) *	2004-07-20	2006-01-26	Cedars-Sinai Medical Center	Method for reducing the likelihood of the occurrence of cardiac arrhythmias
US7300923B2 (en) *	2004-08-30	2007-11-27	Cv Therapeutics, Inc.	Partial and full agonists of A1 adenosine receptors
CN104644627A (zh)	2004-09-14	2015-05-27	科罗拉多大学董事会	基于基因靶向使用布新洛尔的治疗方法
US7822474B2 (en) *	2005-11-30	2010-10-26	Cedars-Sinai Medical Center	Methods for the prediction of arrhythmias and prevention of sudden cardiac death
CA2640089C (en)	2006-02-03	2013-07-23	Cv Therapeutics, Inc.	Process for preparing an a2a-adenosine receptor agonist and its polymorphs
KR101425579B1 (ko)	2006-05-29	2014-08-13	하이버네이션 테라퓨틱스 리미티드	개선된 조직 유지법
WO2008011670A1 (en)	2006-07-25	2008-01-31	Hibernation Therapeutics Limited	Trauma therapy
US20100119554A1 (en)	2007-03-02	2010-05-13	Hibernation Therapeutics Limited	Transplants
ES2397126T3 (es) *	2007-12-21	2013-03-04	Aop Orphan Pharmaceuticals Ag	Composición farmacéutica para la administración parenteral de un antagonista del receptor beta-adrenérgico de acción ultrarrápida
KR20110063556A (ko) *	2008-09-29	2011-06-10	길리애드 사이언시즈, 인코포레이티드	다검출 전산화 단층 촬영법에 사용하기 위한 ａ-２-알파 수용체 길항제와 속도 조절제의 조합물
GB0903299D0 (en) *	2009-02-26	2009-04-08	Guys And St Thomas Nhs Foundat	Composition and methods
ES3003038T3 (en) *	2009-03-18	2025-03-10	Incarda Therapeutics Inc	Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2011019752A2 (en)	2009-08-14	2011-02-17	Gilead Palo Alto, Inc.	A1 adenosine receptor agonist polymorphs
JP2013516495A (ja)	2010-01-11	2013-05-13	イノテックファーマシューティカルズコーポレイション	眼圧を低下させる組合せ、キット、および方法
PT2555776T (pt) *	2010-03-19	2017-02-01	Inotek Pharmaceuticals Corp	Composições de combinação de agonistas de adenosina a1 e bloqueadores não selectivos dos receptores adrenérgicos beta para redução da pressão intra-ocular
JP2013523739A (ja)	2010-03-26	2013-06-17	イノテックファーマシューティカルズコーポレイション	Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
US20120005128A1 (en) *	2010-06-29	2012-01-05	Sanofi	Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
SMT201700377T1 (it)	2012-01-26	2017-09-07	Inotek Pharmaceuticals Corp	Polimorfi anidri di (2r,3s,4r,5r)-5-(6-(ciclopentilammino)-9h-purin-9-il)-3,4- diidrossitetraidrofuran-2-il)}metil nitrato e processi di sua preparazione
NZ630759A (en)	2013-03-15	2017-07-28	Inotek Pharmaceuticals Corp	Ophthalmic formulations comprising an a1 agonist
AU2014292827A1 (en)	2013-07-17	2016-02-04	Hibernation Therapeutics, A Kf Llc	A method for organ arrest, protection and preservation and reducing tissue injury
WO2015089494A1 (en) *	2013-12-13	2015-06-18	Ankenman Ralph	Compositions and methods for treating dysregulated systems
WO2017136421A1 (en)	2016-02-01	2017-08-10	Incarda Therapeutics, Inc.	Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
CN106370754B (zh) *	2016-11-07	2019-03-08	西安科技大学	基于手性高效液相色谱-质谱/质谱技术定量检测布新洛尔光学异构体含量的方法
CA3060702A1 (en)	2017-05-10	2018-11-15	Incarda Therapeutics, Inc.	Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US10744087B2 (en)	2018-03-22	2020-08-18	Incarda Therapeutics, Inc.	Method to slow ventricular rate
US10799138B2 (en)	2018-04-05	2020-10-13	University Of Maryland, Baltimore	Method of administering sotalol IV/switch
US11344518B2 (en)	2018-08-14	2022-05-31	AltaThera Pharmaceuticals LLC	Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11696902B2 (en)	2018-08-14	2023-07-11	AltaThera Pharmaceuticals, LLC	Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en)	2021-08-20	2023-03-21	AltaThera Pharmaceuticals LLC	Antiarrhythmic drug dosing methods, medical devices, and systems
US10512620B1 (en)	2018-08-14	2019-12-24	AltaThera Pharmaceuticals, LLC	Method of initiating and escalating sotalol hydrochloride dosing
US12396970B2 (en)	2021-08-20	2025-08-26	AltaThera Pharmaceuticals LLC	Anti-arrhythmic compositions and methods
JP7156154B2 (ja) *	2019-04-18	2022-10-19	株式会社島津製作所	培地処理システム及び培地処理方法
KR20250171439A (ko)	2019-08-01	2025-12-08	인카다 테라퓨틱스, 인크.	항부정맥 제제
US11007185B2 (en)	2019-08-01	2021-05-18	Incarda Therapeutics, Inc.	Antiarrhythmic formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5108363A (en) *	1988-02-19	1992-04-28	Gensia Pharmaceuticals, Inc.	Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
US5736528A (en) *	1993-10-28	1998-04-07	University Of Florida Research Foundation, Inc.	N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
CA2257948A1 (en) *	1996-06-28	1998-01-08	Merck & Co., Inc.	Antiarrhythmic combinations of selective iks antagonists with beta-adenergic blocking agents
US5789416B1 (en) *	1996-08-27	1999-10-05	Cv Therapeutics Inc	N6 mono heterocyclic substituted adenosine derivatives
JP2001509808A (ja) *	1997-01-31	2001-07-24	ザボードオブトラスティーズオブザリーランドスタンフォードジュニアユニバーシティ	多機能性カルシウム／カルモジュリン−依存性プロテインキナーゼの阻害による不整脈の処置
CO5180581A1 (es) *	1999-09-30	2002-07-30	Pfizer Prod Inc	Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
AU4138601A (en) *	1999-12-03	2001-06-12	Cv Therapeutics, Inc.	Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
US6605597B1 (en) *	1999-12-03	2003-08-12	Cv Therapeutics, Inc.	Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
JP2004508336A (ja) *	2000-09-08	2004-03-18	スィーヴィー　セラピューティクス　インコーポレイテッド	抗不整脈薬としてのプリンリボシド
US6946449B2 (en) *	2001-07-13	2005-09-20	Cv Therapeutics, Inc.	Partial and full agonists of A1 adenosine receptors
ATE418991T1 (de) *	2002-04-18	2009-01-15	Cv Therapeutics Inc	Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker

2003
- 2003-04-18 AT AT03724098T patent/ATE418991T1/de not_active IP Right Cessation
- 2003-04-18 EP EP03724098A patent/EP1494685B1/de not_active Expired - Lifetime
- 2003-04-18 AU AU2003235466A patent/AU2003235466C1/en not_active Ceased
- 2003-04-18 KR KR10-2004-7016764A patent/KR20040106354A/ko not_active Abandoned
- 2003-04-18 RU RU2004130826/14A patent/RU2332220C2/ru not_active IP Right Cessation
- 2003-04-18 CN CNA2008101711378A patent/CN101385738A/zh active Pending
- 2003-04-18 US US10/418,654 patent/US7005425B2/en not_active Expired - Fee Related
- 2003-04-18 NZ NZ536001A patent/NZ536001A/en not_active IP Right Cessation
- 2003-04-18 CN CNA038086999A patent/CN1646142A/zh active Pending
- 2003-04-18 CA CA002482928A patent/CA2482928A1/en not_active Abandoned
- 2003-04-18 ES ES03724098T patent/ES2318129T3/es not_active Expired - Lifetime
- 2003-04-18 WO PCT/US2003/012043 patent/WO2003088978A1/en not_active Ceased
- 2003-04-18 JP JP2003585730A patent/JP2005530736A/ja active Pending
- 2003-04-18 MX MXPA04010285A patent/MXPA04010285A/es active IP Right Grant
- 2003-04-18 DE DE60325572T patent/DE60325572D1/de not_active Expired - Lifetime
2004
- 2004-10-18 ZA ZA200408411A patent/ZA200408411B/en unknown
- 2004-10-18 IL IL16465204A patent/IL164652A0/xx unknown
- 2004-11-17 NO NO20045005A patent/NO20045005L/no not_active Application Discontinuation
2005
- 2005-10-28 US US11/262,025 patent/US7479485B2/en not_active Expired - Fee Related
2009
- 2009-01-09 US US12/351,731 patent/US20090118221A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20030216349A1 (en)	2003-11-20
US7005425B2 (en)	2006-02-28
CA2482928A1 (en)	2003-10-30
KR20040106354A (ko)	2004-12-17
NZ536001A (en)	2006-05-26
US7479485B2 (en)	2009-01-20
US20090118221A1 (en)	2009-05-07
WO2003088978A1 (en)	2003-10-30
NO20045005L (no)	2004-11-17
RU2004130826A (ru)	2005-05-10
ZA200408411B (en)	2006-02-22
ES2318129T3 (es)	2009-05-01
EP1494685A1 (de)	2005-01-12
CN101385738A (zh)	2009-03-18
JP2005530736A (ja)	2005-10-13
AU2003235466A1 (en)	2003-11-03
ATE418991T1 (de)	2009-01-15
DE60325572D1 (de)	2009-02-12
MXPA04010285A (es)	2005-02-03
US20060052333A1 (en)	2006-03-09
AU2003235466C1 (en)	2008-03-20
EP1494685B1 (de)	2008-12-31
RU2332220C2 (ru)	2008-08-27
CN1646142A (zh)	2005-07-27

Publication	Publication Date	Title
NO20045005L (no)	2004-11-17	Fremgangsmate for behandling av arytmier som omfatter administrering av en A1-adenosinagonist med en betablokker, kalsiumkanalblokker eller et hjerteglykosid
WO2004043377A3 (en)	2004-08-05	Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2003097052A3 (en)	2003-12-18	Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MXPA05012155A (es)	2006-02-22	Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
ES2158778A1 (es)	2001-09-01	Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.
CA2146973A1 (en)	1994-05-11	Uses of tgf-.beta. receptor fragment as a therapeutic agent
AP2002002458A0 (en)	2002-06-30	Compounds for the treatment of ischemia.
WO2004006859A3 (en)	2004-07-01	Platinum compound
AU1810001A (en)	2001-06-12	Compounds, compositions, and methods for stimulating neuronal growth and elongation
GB9621771D0 (en)	1996-12-11	Method of treatment of heart disease
MY129445A (en)	2007-04-30	Compositions for treating inflammatory response
AU2001292579A1 (en)	2002-04-15	Methods and compounds for treating proliferative diseases
WO2005046593A3 (en)	2006-03-02	Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
GB2297691B (en)	1998-09-16	Method for improving breeding activity of boars by using feed for the breeding boars
WO2004012746A3 (en)	2004-08-05	New uses for inhibitors of inosine monophosphate dehydrogenase
AU2002342808A1 (en)	2004-05-04	Extract with anti-tumor and anti-poisonous activity
MXPA04005207A (es)	2004-08-19	Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos.
PL376346A1 (en)	2005-12-27	Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration
AU4937499A (en)	2000-09-21	Use of succinic acid or salts thereof and method of treating insulin resistance
AU3360000A (en)	2000-08-29	Use of 4-amino pyridine for treatment of peripheral neuropathies
SI1196172T1 (sl)	2006-06-30	(S,S)-reboksetin za zdravljenje kronicne bolecine
ZA988009B (en)	2000-03-22	Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy.
AU9259101A (en)	2002-03-22	Purine ribosides as antiarrhythmics
ES3066586T3 (en)	2026-05-13	Novel adenosine and 1,n6-ethenoadenosine derivatives for cancer treatment
EP0904094A4 (de)	2002-06-26	Behandlung von knochenleiden mit adrenomedullin